The CD133+ population is identified by the promoter hypomethylation in several cancers such as ovarian, glioblastoma, and colorectal when compared to the CD133- population (Tabu et al., 2008; Yi et al., 2008; Baba et al., 2009). Here, PROM1 is linked to cancer.